Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment

Shuichi Sato; Tatsuya Miyake; Masatoshi Kataoka; Kazuki Isoda; Tomotaka Yazaki; Hiroshi Tobita; Norihisa Ishimura; Yoshikazu Kinoshita

doi:10.2169/internalmedicine.8791-16

CASE REPORTS

Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment

Shuichi Sato, Tatsuya Miyake, Masatoshi Kataoka, Kazuki Isoda, Tomotaka Yazaki, Hiroshi Tobita, Norihisa Ishimura, Yoshikazu Kinoshita

Author information

Shuichi Sato
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Tatsuya Miyake
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Masatoshi Kataoka
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Kazuki Isoda
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Tomotaka Yazaki
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Hiroshi Tobita
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Norihisa Ishimura
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan
Yoshikazu Kinoshita
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan

Keywords: lusutrombopag, thrombocytopenia, chronic liver disease, invasive procedure, hepatocellular carcinoma

JOURNAL OPEN ACCESS

2017 Volume 56 Issue 21 Pages 2887-2890

DOI https://doi.org/10.2169/internalmedicine.8791-16

Browse “Advance online publication” version

Details

Abstract

The efficacy of repeated lusutrombopag administration for thrombocytopenia in patients with chronic liver disease who undergo two or more planned invasive procedures is unknown. We herein report our findings regarding the effects of repeated lusutrombopag administration given to avoid platelet transfusion in a patient with chronic liver disease and thrombocytopenia. The platelet count showed a positive response to lusutrombopag treatment prior to the initial invasive procedure to treat a hepatoma, so platelet transfusion was not necessary. In conclusion, lusutrombopag may be a useful drug for patients with thrombocytopenia to avoid platelet transfusion in those undergoing two or more planned invasive procedures.

Corresponding author

Register with J-STAGE for free!